NexPoint Real Estate Finance, Inc.

Thank you for standing by. My name is Kate and I will be your conference operator today. At this time, I would like to welcome everyone to the next point, real estate finance Q4 2024 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed with the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Kristen Griffith, Investor Relations. Please go ahead.

Thank you. Good day, everyone, and welcome to Next Point Real Estate Finance Conference Call to review the company's results for the fourth quarter ended December 31st, 2024. On the call today are Paul Richards, Executive Vice President and Chief Financial Officer, and Matt McGrain, Executive Vice President and Chief Investment Officer. As a reminder, this call is being webcast through the company's website at nref.nextpoint.com. Before we begin, I would like to remind everyone that this conference call contains forward-looking statements within the meanings of the Private Securities Litigation Reform Act of 1995 that are based on management's current expectations, assumptions, and beliefs. Listeners should not place undue reliance on any forward-looking statements and are encouraged to review the company's annual report on Form 10-K and accompanies other filings with the SEC for a more complete discussion of risk and other factors that could affect forward-looking statements. The statements made during this conference call speak only as of today's date and except as required by law, NREF does not undertake any obligation to publicly update or revise any forward-looking statements. This conference call also includes an analysis of non-GAAP financial measures. For a more complete discussion of these non-GAAP financial measures, see the company's presentation that was filed earlier today. I would now like to turn the call over to Matt McGrainer. Please go ahead, Matt.

Thank you, Kristen. And before we dive into our prepared remarks, I want to take a moment to congratulate Brian Mitz on his well-earned retirement, which officially took effect on December 31st of 2024. We're incredibly grateful for his years of dedication, the countless long days he put in, and the instrumental role he played in shaping NREF into what it is today. While Brian has stepped back from the day-to-day operations, we're fortunate that he remains a valued member of our board, continuing to provide guidance and insight as we move forward. At the same time, I'm pleased to officially welcome Paul Richards as our new CFO. While most of you on the phone already know his capabilities, having worked closely with Brian and me for over decades, Paul deeply understands our strategy and our approach to execution. He's a strong leader, and I have full confidence in his ability to continue to drive sector-leading long-term results for NREF shareholders. With that, I'll turn the call over to Paul to walk us through our fourth quarter and four-year 2024 financial results and to discuss the portfolio.

Thanks, Matt. Thank you, Kristen. And welcome to everyone joining us this morning. I'm going to briefly discuss our quarterly and year-to-date results, move to our balance sheet, and lastly provide guidance for the next quarter before turning it over to Matt for a detailed commentary on the portfolio and the macro lending environment. Q4 results are as follows. For the fourth quarter, we reported a net income of $0.43 per diluted share compared to net income of $0.73 per diluted share for the fourth quarter of 2023. The decrease in net income for the quarter was due to unrealized loss on our common stock investments and a decrease in change in net assets on CMBS VIEs between the fourth quarter of 2024 and the fourth quarter of 2023. Interest income decreased by $15.4 million to $32.3 million in the fourth quarter of 2024 from $16.9 million in the fourth quarter of 2023. The increase was driven by an increase in interest income driven by higher rates. Interest expense decreased 2.5 million in the fourth quarter of 2024 compared to the same period in the prior year from the deleveraging that occurred in the first quarter of this year. Earnings available for distribution were 83 cents per diluted common share in Q4 compared to 44 cents per diluted common share in the same period of 2023. Cash available for distribution was 47 cents per diluted common share in Q4 compared to 51 cents per diluted common share in the same period of 2023. The increase in earnings available for distribution was driven by the increase in net income for the quarter. We paid a regular dividend of 50 cents per share in the fourth quarter, and the board has declared a dividend of 50 cents per share payable for the first quarter of 2025. Our dividend in the fourth quarter was 0.94 times covered by cash available for distribution. Book value per share increased full basis points from Q3 2024 to $16.97 per diluted common share, with the increase being primarily due to unrealized gain on our preferred stock investments. During the quarter, we funded $16.7 million on a life science development property in Cambridge, Massachusetts, and we redeemed $9.5 million of mortgage-backed securities. During the fourth quarter, we sold 1.7 million shares of our Series B cumulative redeemable preferred for net proceeds of 38.8 million. Full year results are as follows. For the full year of 2024, we reported net income of $1.02 per diluted share compared to net income of $0.60 per diluted share for the year ended 2023. The increase in net income for the year was primarily due to an increase in net interest income. Interest income increased by $4.2 million, $72.5 million for the year ended 2024 from $68.4 million for the year ended 2023. The increase is driven by an increase in interest income driven by higher rates. Also, interest expense decreased during the year from the deleveraging event that occurred in the first quarter. Earnings available for distribution was $1.78 per diluted share year-to-date compared to $1.88 per diluted share in the same period of 2023. for a decrease of 5.3%. Cash available for distribution was $2.42 per diluted share year-to-day compared to $2.05 per diluted share in the same period of 2023 for an increase of 18%. Moving to the portfolio and balance sheet. Our portfolio is comprised of 83 investments with an outstanding balance of $1.2 billion. Our investments are allocated across sectors as follows. 15.5% single-family rental, 49.7% multifamily, 31% life sciences, 1.5% self-storage, 1.8% specialty manufacturing, and lastly, a 60 basis points marina. Our fixed income portfolio is allocated across investments as follows. 10.5% senior loans, 29.3% CMBSB pieces, 19.5% preferred equity investments, 23.7% mezzanine loans, 3.9% IO strips, 12.9% revolving credit facilities, and 30 basis points promissory notes. The assets collateralizing our investments are allocated geographically as follows. 15% Texas, 25% Massachusetts, 8% California, 6% Georgia, 4% Florida, 4% Maryland, with remaining across states less than 4% exposure, reflecting our heavy preference for Sunbelt markets, with the Massachusetts and California exposure heavily weighted towards the life science. The collateral on our portfolio is 76.5% stabilized with a 59.2% loan-to-value and a weighted average DSCR of 1.32 times. We have $799.3 million of debt outstanding. Of this, $400.9 million, or 50.2%, is short-term. Our weighted average cost of debt is 6% and has a weighted average maturity of 1.4 years. Our debt is collateralized by $862.8 million of collateral with a weighted average maturity of 1 year. Our debt to equity ratio is 1.39 times. Guidance. Moving to guidance for the first quarter, we are guiding to earnings available for distribution and cash available for distribution as follows. Earnings available for distribution of 45 cents per diluted common share at the midpoint with a range of 40 cents on the low end and 50 cents in the high end. Cash available for distribution of 50 cents per diluted common share at the midpoint with a range of 45 cents in the low end and 55 cents in the high end. Now I'd like to turn it over to Matt for a detailed discussion of the portfolio and markets.

Thank you, Paul. We continue to be pleased with our differentiated results for the quarter and in a year in which there were many challenges in the commercial real estate sector. Our underlying credit profile of the portfolio remains very strong, and there is reason for more growth and optimism in 2025. For one, multifamily fundamentals continue to improve. Most industry participants, including us, are expecting an inflection as supply continues to wane. Q4 starts for just 37,000 units for the quarter, the lowest level since Q4 of 2011. We're expecting new lease growth to turn positive in the second half of the year, which should drive more transaction activity, liquidity, and opportunity to put capital to work. Indeed, you will likely see growth in our multifamily portfolio in the next couple of quarters across construction financing, Freddie K deals, and high-quality MES opportunities. Our storage exposure also remains very compelling, with same-store NOIs flat to slightly positive. Like the multifamily market, we expect more growth in rates in the back half of the year. And here recently, we have built a quality pipeline of construction financing opportunities with attractive yields on costs and repeat sponsors from the journey and capital days. We expect these opportunities to reach approximately $75 million over the next couple of quarters. Life science tour activity and capital planning have also picked up, and we're seeing a flurry of activity recently, especially on the advanced manufacturing and GMP sides. We are actively underwriting $300 billion of opportunities across infrastructure and pharmaceutical manufacturing today. We've liked the reshoring of supply chain story for a while now, and the recent tariff threats that may have sparked billions of reshoring by Apple, Lilly, and others should exacerbate this trend going forward. Finally, we're pleased with the capital options available to us to fund this growth. With where we are in the balance sheet and the success we're having with the Series B raise, we still have multiple creative avenues to fund growth, including A-note warehouses and even a bond-rated deal, a rated bond deal. To close, we're excited about the company's prospects in 2025 and the continued stability of our portfolio and, of course, the opportunity to go on offense in this environment. As always, I want to thank the team here for their hard work, and now we'd like to turn the call over to the operator for questions.

At this time, I would like to remind everyone in order to ask a question, press star then the number one on your telephone keypad. We will pause for just a moment to compile the Q&A roster. Your first question comes from the line of Stephen Laws with Raymond James. Please go ahead.

Hi, good morning. Good morning. Matt, you may have touched on this, you did touch on it a second ago with your comment You said construction, Freddie K., are likely to be kind of new investments near term. Can you talk about the returns you're seeing on those new investments, how that compares to other things in your pipeline, and how you think about how accretive new investments are compared to the cost of the Series B capital as you raise more?

Yeah, it's a good question. On the Freddie K, we're hearing from Freddie, we're most likely going to get a five-year fixed deal here in the second quarter, be anywhere from $30 to $50 million in gross value. We would plan to lightly repo that, expect the yields to be in the 8% to 9% range. So, you know, getting with a little bit of accretive leverage, we're kind of, you know, low to mid-teens type of return. So that still remains attractive, especially given the credit profile. of Freddie K deals and deals originated in 2025. So the risk reward there we view is very, very attractive. On the construction side, we're seeing really high-quality assets and developments with well-heeled developers that we can, you know, do a 60% loan-to-cost, you know, 300 to 400 spread. And then we have accretive A-note lenders at the same time. So, yeah. That capital takes longer to put out, but we do have some attractive A note opportunities against the Series B that we would use to fund. So I like both of those investments.

Great. Can you touch maybe a little bit on the life sciences investments and performance there? I mean, any key metrics or You know, attachment points, performance, you know, that's grown materially over the past year as a percentage or a mix of the portfolio. You know, what's the best way for us to monitor that as we look at the metrics that you release in your, you know, public filings?

Yeah, it's a good question. You know, it's chunky in terms of the two main life science investments. Let me start with the Massachusetts loan and ALY, it's a $220 million commitment. of which we funded roughly $175 million. The detachment point on a loan-to-cost basis for that asset is roughly 25% loan-to-cost, a stabilized debt yield for rents in just the 80s. for that deal would be 30-plus percent. More importantly, though, the buildings or that development has three buildings, 395,000 square feet today. All of them are topped out, skinned, and amenities and spec suites are going in. So there's, like I said in the prepared comments, a flurry activity on that asset in particular. And most importantly, I have a bid for that loan far south of where, you know, where we have or where our interest rate is. It's over plus 900. So I feel really good about that. And then across the rest of the loan portfolio, we really haven't seen the type of leasing activity in quite some time, the past 18 months or so. The remainder of the facility are kind of detached reports in the, I'd say, 40% to 50% range, somewhere in the avenue of 800% to 900%. dollars a foot detachment point where these assets are $1,600, $1,700, $1,800 a foot to build, and these assets are first to fill. So I really think that what we're doing there is pretty smart, and I think we'll be proven right.

Great. And finally, you know, update on loan performance, any, you know, delinquent or defaulted loans or any watch list loans. I know you guys have, you know, very few of those, if any, historically curious for update at your end.

Yeah. Hey, Steve. This is Paul. We have a few in our CMBS portfolio that we're keeping an eye on. But, you know, as you know, with these Freddie K deals, you know, we call them bulletproof paper. But we have our eye on, you know, a few watch list loans. In terms of a few prep deals, there's refinancing activity for one of these package deals that we have in our backyard. And we're giving time for one of the sponsors to go through a refinancing. And so we expect that refinancing to happen. I would say Q2, maybe Q3, but I think it's probably going to be a Q2 event on a refinancing for a few of those prep deals. But overall, extremely strong portfolio performance and extremely happy with the results.

Great. Appreciate the comments this morning. Thank you. Thanks, Stephen.

Your next question comes from the line of Jade Romani with KBW. Please go ahead.

Thank you. On the Cambridge deal, is that purely spec, since it's so large, wondering if there's an anchor tenant or any initial leasing? When do you expect to be able to provide an update as to how that's going?

Yeah, we expect to have – or the developer expects to have the CFO in Q3. There is pre-leasing activity right now. Like I said, I think I mentioned upwards of 300,000 square feet on a total build of 395,000 square feet. You know, the developer is seeing both, you know, 25,000 to 50,000 square foot chunks, but there is a couple of larger requirements in the west and east Cambridge areas floating around right now that are actively touring the asset and are looking for a Q3 or Q4, you know, Q3 or Q4 move-in. I would expect by then we'll have some pretty good traction and some good news to report.

And just to clarify, is it a spec development?

Yeah, it is spec.

Okay. Because, you know, all the data from the brokerage firms and also some of the mortgage REITs that have like science exposure has not been good in terms of leasing i mean i think in aggregate the sector seems to be entering the beginnings of a stabilization uh vc funding is picking up and you're seeing some of the large you know pharma companies uh make some leasing decisions but by and large we're still missing a lot of the you know nascent uh players in the space that drove some of the leasing in spec development so I guess, what gives you confidence that this asset in particular will be able to buck the trend of oversupply that we're seeing?

A couple things, because most of the literature written as far as supplies is wrong. I think ARE put out the true competitive supply to a new purpose-built life science facility in Boston. I think you would hear quotes, and maybe this is what you're referring to, of like 16 million square feet of new supply coming online. The reality is in the core kind of three markets where you want to be, there's less than 2 million and probably 50% of that isn't going to be delivered. At the same time, you're having, and I'm seeing it, multiple requirements and tours for this facility in particular. And then, you know, notwithstanding any of the first two reasons that I think will be successful, again, I have a bid for the loan. And, you know, we're 25% loan to cost, which is less than land value and across 27 and a half acres in Cambridge. So pretty comfortable.

And who's the bid for the loan from? I mean, you don't have to name who, of course, but the type of entity, is that private credit, like a debt fund or... some other entity of that kind?

It's a strategic REIT.

Okay. Got it. And then the language that says no, you always say no loans and forbearance. I guess that's not true because of Paul's comments that there's a couple of deals on the watch list right now.

Yeah, it's not necessarily they're on the watch list. It's the borrower is refinancing into a recap loan, and we're just giving him a 90-day period in which we'll pick the interest so he doesn't have to pay it current so we can get paid off.

Do you happen to know what the delinquency rate is in the Freddie Mac K-Series portfolios?

Overall, the delinquency rate is extremely small. Off the top of my head, I couldn't tell you, but I'll tell you that, you know, there's probably out of the seven B pieces that we have or eight B pieces, there's maybe two loans that are 30 days or 60 days delinquent. So it's extremely small subset.

Okay. That's great. Thanks so much. Thanks, Jared.

I will now turn the call back to the management team for closing remarks.

Yeah, thank you very much for dialing in and appreciate the opportunity to report our results and looking forward to the second quarter or the first quarter results here in a few months. Thank you very much.

Ladies and gentlemen, that concludes today's call. Thank you and have a great day.